Steven Leonard Chapman Sells 3,848 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,848 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $229.08, for a total transaction of $881,499.84. Following the transaction, the chief executive officer directly owned 136,568 shares in the company, valued at $31,284,997.44. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The stock was sold at an average price of $238.07, for a total transaction of $1,047,508.00.
• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88.
• On Tuesday, October 28th, Steven Leonard Chapman sold 3,680 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $704,572.80.
• On Monday, October 27th, Steven Leonard Chapman sold 2,335 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $449,067.20.
• On Tuesday, October 21st, Steven Leonard Chapman sold 1,603 shares of Natera stock. The shares were sold at an average price of $187.95, for a total value of $301,283.85.

Natera Stock Up 4.8%

Natera stock traded up $11.32 during trading hours on Tuesday, hitting $248.74. The stock had a trading volume of 1,550,717 shares, compared to its average volume of 965,766. The company has a 50-day moving average of $224.18 and a two-hundred day moving average of $184.78. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $249.15. The company has a market cap of $34.41 billion, a PE ratio of -108.62 and a beta of 1.62.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. As a group, analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently made changes to their positions in the business. SWS Partners increased its position in Natera by 11.8% during the third quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after buying an additional 4,980 shares during the last quarter. Vontobel Holding Ltd. lifted its position in shares of Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after buying an additional 5,614 shares during the last quarter. Baird Financial Group Inc. boosted its stake in shares of Natera by 277.8% during the 2nd quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after acquiring an additional 19,576 shares during the period. Park Avenue Securities LLC acquired a new position in shares of Natera during the 2nd quarter worth approximately $1,525,000. Finally, Orion Porfolio Solutions LLC increased its holdings in shares of Natera by 68.8% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock worth $2,051,000 after acquiring an additional 4,946 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on NTRA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price objective on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Barclays increased their target price on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. BTIG Research boosted their price target on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Finally, Piper Sandler increased their price objective on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Fifteen investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.29.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.